Is the efficacy of successful infliximab induction therapy maintained for one year lasting without retreatment in different behavior types of Crohn's disease?

Journal of Crohn's and Colitis

Volumn 2, Issue 4, 2008, Pages 322-326

  Molnar T ^a   Farkas, K ^a   Miheller, P ^b   Nyari T ^a   Szepes, Z ^a   Herszenyi L ^b   Müzes, Gy ^b   Nagy, F ^a   Tulassay, Zs ^b   Wittmann, T ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Crohn's disease; Infliximab induction therapy; On demand treatment

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; STEROID;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; GRAFT REJECTION; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRIORITY JOURNAL; REMISSION; TREATMENT DURATION;

EID: 56449111531     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2008.07.003     Document Type: Article

References (8)

1. D'Haens G., Baert F., van Assche G., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371 (2008) 660-667
2. Lennard-Jones J.L. Classification of inflammatory bowel disease. Scand J Gastroenterol 24 suppl (1989) 2-6
3. Lichtenstein G.R., Abreu M.T., Cohen R., and Tremaine W. American gastroenterological association institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130 (2006) 940-987
4. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 359 (2002) 1541-1549
5. Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Eng J Med 350 (2004) 934-936
6. Doménech E., Hinojosa J., Nos P., et al. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?. Aliment Pharmacol Ther 22 (2005) 1107-1113
7. Chaudhary R., and Ghosh S. Prediction of response to infliximab in Crohn's disease. Dig Liver Dis 37 (2005) 559-563
8. Parsi M.A., Achkar J., Richardson S., et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology (2002) 707-713